Pfizer Consumer Healthcare Italy S.r.l., leader in the research, production and commercialisation of medicinal products, has chosen to include the Sucrosomial® Magnesium in the ingredients of its new Multicentrum My Mag. The product, available in
This acknowledgement is especially important and prestigious for both the company and the innovative Sucrosomial® Technology, a unique, patented system that enables minerals to cross the gastric environment without obstacles; thus guaranteeing tolerability and high absorption levels. A patent that is already the base of several PharmaNutra brand products, like those in the SiderAL® line (Sucrosomial® Iron) and UltraMag® (Sucrosomial® Magnesium) itself which, in any case, will remain the market's sole product with a 100% Sucrosomial® formula.
The agreement with Pfizer was stipulated by
"The agreement we have signed with Pfizer to use our Sucrosomial® Magnesium in their new Multicentrum My Mag is a key step for our company growth and opens stimulating, new scenarios," declares the President
Founded and led by the President
Contact Details:
Chief Marketing and Communication Officer
+39 345 3646330
g.gracci@pharmanutra.it
Investor Relations Pharmanutra
+39 050 7846500
investorrelation@pharmanutra.it
Spriano Communication Press Office
+39 346 0477901
ctronconi@sprianocommunication.com
Spriano Communication Press Office
+39 347 9834881
mrusso@sprianocommunication.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/pharmanutra-spa-pfizer-invests-in-sucrosomial-technology-301042323.html
SOURCE
© Canada Newswire, source